<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/research-analysts-recent-ratings-updates-for-zosano-pharma-zsan.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T07:44:41+00:00"/>
    <meta property="og:title" content="Research Analysts’ Recent Ratings Updates for Zosano Pharma (ZSAN)"/>
    <meta property="og:description" content="Zosano Pharma (NASDAQ: ZSAN) has recently received a number of price target changes and ratings updates: 11/21/2019 – Zosano Pharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.25 price target on the stock. According to Zacks, “Zosano Pharma Corporation is a biopharmaceutical […]"/>
  </head>
  <body>
    <article>
      <h1>Research Analysts’ Recent Ratings Updates for Zosano Pharma (ZSAN)</h1>
      <address><time datetime="2019-11-25T07:44:41+00:00">25 Nov 2019, 07:44</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/zosano-pharma-corp-logo.png"/>
      </figure>
      <p><b>Zosano Pharma</b> (NASDAQ: ZSAN) has recently received a number of price target changes and ratings updates:</p>
      <ul>
        <li>11/21/2019 – Zosano Pharma was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “hold” rating to a “buy” rating. They now have a $2.25 price target on the stock. According to Zacks, “Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company’s lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California. “</li>
        <li>11/15/2019 – Zosano Pharma had its price target lowered by analysts at Cantor Fitzgerald from $12.00 to $6.00. They now have an “overweight” rating on the stock.</li>
        <li>11/15/2019 – Zosano Pharma had its price target lowered by analysts at BTIG Research to $16.00. They now have an “in-line” rating on the stock.</li>
        <li>11/15/2019 – Zosano Pharma had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $8.00 price target on the stock.</li>
        <li>10/19/2019 – Zosano Pharma was downgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “buy” rating to a “hold” rating. According to Zacks, “Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company’s lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California. “</li>
      </ul>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/ZSAN/price-target/">NASDAQ:ZSAN</a> opened at $1.64 on Monday. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average is $1.94 and its two-hundred day moving average is $2.53. Zosano Pharma Corp has a 52 week low of $1.41 and a 52 week high of $6.65. The company has a market cap of $30.81 million, a PE ratio of -0.44 and a beta of 2.67.</p>
      <p>Zosano Pharma (NASDAQ:ZSAN) last released its earnings results on Thursday, November 14th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.03. As a group, sell-side analysts expect that Zosano Pharma Corp will post -2.08 EPS for the current fiscal year.</p>
      <p>A number of large investors have recently added to or reduced their stakes in ZSAN. FNY Investment Advisers LLC bought a new stake in shares of Zosano Pharma in the 3rd quarter worth approximately $234,000. Jane Street Group LLC bought a new stake in shares of Zosano Pharma in the 2nd quarter worth approximately $36,000. Vanguard Group Inc. lifted its holdings in shares of Zosano Pharma by 118.6% in the 2nd quarter. Vanguard Group Inc. now owns 957,025 shares of the biotechnology company’s stock worth $3,129,000 after purchasing an additional 519,305 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Zosano Pharma by 17.7% in the 2nd quarter. BlackRock Inc. now owns 366,876 shares of the biotechnology company’s stock worth $1,200,000 after purchasing an additional 55,105 shares during the last quarter. Finally, Aisling Capital Management LP lifted its holdings in shares of Zosano Pharma by 900.0% in the 2nd quarter. Aisling Capital Management LP now owns 16,000,000 shares of the biotechnology company’s stock worth $5,232,000 after purchasing an additional 14,400,000 shares during the last quarter. 34.33% of the stock is currently owned by institutional investors.</p>
      <p>Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/difference-between-common-shares-and-convertible-shares/">What is the Difference Between Common Shares and Convertible Shares?</a></p>
    </article>
  </body>
</html>